Fulcrum Therapeutics FULC 深 滬
等待開盤 09-25 09:30:00 美东时间
3.785
-0.025
-0.66%
華盛通- 最 高3.82
- 今 開3.82
- 成交量 194.81万股
- 最 低 3.745
- 昨 收 3.81
- 總市值 2.89亿
- 52周最高 15.7399
- 市盈率 靜 --
- 換手率 2.55%
- 52周最低 2.83
- 委 比 37.29%
- 總股本 7629.73万
- 歷史最高 33.098
- 量 比 1.31
- 振 幅 1.97%
- 歷史最低 2.25
- 每 手 1
- 風險率 2.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Are UTZ, VCTR, FULC, CZR Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
08-29 01:50
Fulcrum Therapeutics, Slate Medicines to merge in all-stock deal
Fulcrum Therapeutics (FULC) and Slate Medicines agreed to combine in an all-stock transaction, creating a company focused on developing next-generation migraine therapies. FULC shares jumped nearly +1...
08-17 19:15
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
Fulcrum Therapeutics and Slate Medicines have agreed to merge in an all-stock transaction, with the combined company operating as Slate Medicines. The merger aims to advance Slate's pipeline of next-generation migraine therapeutics, including SLTE-1009, a clinical-stage anti-PACAP/VIP monoclonal antibody. Slate has secured $245 million in private placement financing, expected to fund operations into 2029. The transaction is subject to customary c...
08-17 11:00
Fulcrum Therapeutics Advances Restructuring with Leadership Changes
Fulcrum Therapeutics ( ($FULC) ) has provided an announcement. On May 31, 2026,...
06-12 06:21
What's Going On With Fulcrum Therapeutics Stock On Thursday?
Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins a strategic review.
06-04 22:22
美股大行评级 | 潜在涨幅43%，慧与获11家大行集体上调目标价；最高300美元，Credo获9家大行集体上调目标价
今日重点评级关注：Ascendiant Capital：维持Genasys"买入"评级，目标价从5.5美元升至6美元；Citizens：维持Abivax"跑赢大市"评级，目标价从131美元升至187美元
06-03 11:17
Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3
Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $25 to $3.
06-03 01:57
美国Fulcrum制药公司因安全风险终止多动症新药研发 股价暴跌逾五成并寻求转让
美国生物制药公司Fulcrum Therapeutics（股票代码：FULC.O）2日宣布，因美国食品和药物管理局（FDA）对潜在致癌风险提出严重关切，公司...
06-02 21:56
Fulcrum plunges after discontinuing lead program
Fulcrum Therapeutics (FULC) lost nearly 50% of its value in extended trading after the company disclosed plans to discontinue the development of its lead asset, pociredir, for sickle cell disease in r...
06-02 18:58
